AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported strong financial performance with a 5% revenue increase and improved gross margins. The Med Tech segment showed significant growth, and there's a positive outlook with raised revenue guidance. Although there are risks associated with forward-looking statements, the overall sentiment is positive due to the strong financial results and optimistic future projections.
Key Financial Performance
Revenue Revenue for the third quarter of fiscal 2026 was $91.1 million, representing a 5% increase year-over-year. This growth was driven by strong performance in the Med Tech segment, which grew by 15%, offsetting a slight decline in the Med Device segment.
Gross Margin Gross margin for the quarter was 55.2%, up from 54.5% in the prior year. The improvement was attributed to favorable product mix and operational efficiencies.
Operating Expenses Operating expenses were $45.3 million, up 3% year-over-year. The increase was primarily due to higher R&D investments and increased sales and marketing expenses.
Net Income Net income for the quarter was $4.8 million, compared to $3.5 million in the same period last year, reflecting a 37% increase. This was driven by higher revenue and improved gross margins.
Cash Flow Operating cash flow was $10.2 million, a 20% increase from $8.5 million in the prior year. The improvement was due to better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Risks from forward-looking statements: The company cautions that projections or forward-looking statements regarding future events, including expected revenue, adjusted earnings, and gross margins, may differ materially from actual results due to various factors.
Regulatory and compliance risks: Management encourages reviewing past and future SEC filings, which identify specific factors that may cause actual results to differ materially, indicating potential regulatory or compliance challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expected Revenue: The company will make projections or forward-looking statements regarding expected revenue for fiscal year 2026.
Adjusted Earnings and Gross Margins: The company will make projections or forward-looking statements regarding adjusted earnings and gross margins for fiscal year 2026.
Trends: The company will discuss trends that may continue in the future.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO President
CFO Young
Canaccord Genuity
Capital Markets
Clemmer CEO
Corp Research
Director Stephen
Division EDT
Division Frank
EDT non
Executive VP
Frank Takkinen
Genuity Corp
Investors non
LLC Research
Lake Street
Markets LLC
President Director
Research Division
Stephen Trowbridge
Street Capital
Takkinen Lake
Trowbridge Executive
VP CFO
Young Canaccord
trend Investors
ANGO Transcript
AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript
Positive4-2
The company reported strong financial performance with a 5% revenue increase and improved gross margins. The Med Tech segment showed significant growth, and there's a positive outlook with raised revenue guidance. Although there are risks associated with forward-looking statements, the overall sentiment is positive due to the strong financial results and optimistic future projections.
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
Positive1-6
The earnings call highlights strong financial performance with revenue growth across multiple segments, improved gross margins, and positive cash flow. The raised guidance for fiscal 2026 and increased adjusted EBITDA outlook further support a positive sentiment. Although some risks were noted, such as competitive pressures and international expansion challenges, the overall outlook and strategic initiatives like the Auryon platform's international traction and positive CPT code changes suggest a favorable stock price movement.
AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
ANGO Slides
ANGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
